Adoption Rate of Video-Assisted Thoracic Surgery for Lung Cancer Varies Widely in China

Cai, Jianping; Zhou, Jian; Yang, Fan; Wang, Jun

doi:10.1016/j.chest.2017.12.027

Cited by 5 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In China, video-assisted thoracoscopic surgery (VATS), as a rational alternative to open thoracotomy, was increasingly used [156][157][158]. A retrospective study of 7,726 Chinese NSCLC patients found that VATS lobectomy was related to better perioperative outcomes in comparison with open lobectomy [159].…”

Section: Surgerymentioning

confidence: 99%

“…It is recommended that regional lymph node dissection at least includes three hilar lymph node stations and three mediastinal lymph node stations [ 155 ]. In China, video‐assisted thoracoscopic surgery (VATS), as a rational alternative to open thoracotomy, was increasingly used [ 156 , 157 , 158 ]. A retrospective study of 7,726 Chinese NSCLC patients found that VATS lobectomy was related to better perioperative outcomes in comparison with open lobectomy [ 159 ].…”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Non‐small cell lung cancer in China

Chen

Liu

Wen

et al. 2022

Cancer Communications

279

View full text Add to dashboard Cite

In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors for lung cancer include tobacco use, family history, radiation exposure, and the presence of chronic lung diseases. Most early‐stage non‐small cell lung cancer (NSCLC) patients miss the optimal timing for treatment due to the lack of clinical presentations. Population‐based nationwide screening programs are of significant help in increasing the early detection and survival rates of NSCLC in China. The understanding of molecular carcinogenesis and the identification of oncogenic drivers dramatically facilitate the development of targeted therapy for NSCLC, thus prolonging survival in patients with positive drivers. In the exploration of immune escape mechanisms, programmed cell death protein 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) inhibitor monotherapy and PD‐1/PD‐L1 inhibitor plus chemotherapy have become a standard of care for advanced NSCLC in China. In the Chinese Society of Clinical Oncology's guidelines for NSCLC, maintenance immunotherapy is recommended for locally advanced NSCLC after chemoradiotherapy. Adjuvant immunotherapy and neoadjuvant chemoimmunotherapy will be approved for resectable NSCLC. In this review, we summarized recent advances in NSCLC in China in terms of epidemiology, biology, molecular pathology, pathogenesis, screening, diagnosis, targeted therapy, and immunotherapy.

show abstract

Section: Surgerymentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

Non‐small cell lung cancer in China

Chen

Liu

Wen

et al. 2022

Cancer Communications

279

View full text Add to dashboard Cite

show abstract

“…In recent years, minimally invasive procedure has developed rapidly and become as mainstream approach especially in thoracic surgery [12][13][14]. Improvements in equipment and technology have made it possible to perform minor and major pulmonary resections by complete VATS: such as lung biopsy, wedge resection, sleeve resection and even pneumonectomy.…”

Section: The Effectiveness and Feasibility Of Thoracoscopic Reoperationmentioning

confidence: 99%

Is VATS approach suitable in re-operations for postoperative hemothorax after pulmonary resection? Data analysis in a big volume thoracic center

Gao

et al. 2022

J Cardiothorac Surg

View full text Add to dashboard Cite

Objective This study explored the safety and of feasibility of video-assisted thoracoscopy (VATS) in re-operations for post-operative hemothorax. Methods The clinical data of patients underwent re-operations due to post-operative hemothorax after pulmonary resection in Shanghai Pulmonary Hospital from 2006 to 2018 were retrospectively analysed. The incidence of re-operations were analyzed. The mortality and morbidity were compared between thoracotomy and thoracoscopic procedure for re-exploration. Results A total of 114 patients were included. The annual incidence rate ranged from 0.21 to 0.54%; the perioperative mortality was 2.6%; there were 114 cases of re-operations for hemothorax after 2012, including 62 cases in thoracoscopy group and 52 cases in open group. The durations of chest-tube drainage (7.2 ± 3.9 days vs 10.9 ± 12.0 days, P = 0.001) and length of stay in hospital (13.7 ± 6.7 days vs 18.9 ± 10.6 days, P = 0.002) in the thoracoscopic group were shorter than those in the open group. The thoracoscopic group had fewer post-operative complications as well (P = 0.023). Meanwhile, post-operative complications in the delayed group were significantly higher than those in the non-delayed group, with a longer length of hospital stay and higher hospitalization costs. Conclusion Complete VATS is safe and feasible for re-operation due to post-operative hemothorax and can be an alternative to thoracotomy. Delayed re-operations are associated with more post-operative complications and higher costs.

show abstract

UniPortal thoracoscopic pneumonectomy does not compromise perioperative and long-term survival in patients with NSCLC: A retrospective, multicenter, and propensity score matching study

Gao

Zhang

et al. 2021

Lung Cancer

View full text Add to dashboard Cite

Adoption Rate of Video-Assisted Thoracic Surgery for Lung Cancer Varies Widely in China

Cited by 5 publications

References 3 publications

Non‐small cell lung cancer in China

Non‐small cell lung cancer in China

Is VATS approach suitable in re-operations for postoperative hemothorax after pulmonary resection? Data analysis in a big volume thoracic center

UniPortal thoracoscopic pneumonectomy does not compromise perioperative and long-term survival in patients with NSCLC: A retrospective, multicenter, and propensity score matching study

Contact Info

Product

Resources

About